Head of Private Equity Banking at Aegis Capital
Adam K. Stern
Head of Private Equity Banking at Aegis Capital and CEO of SternAegis Ventures.
Formerly the Senior Managing Director of Spencer Trask Ventures. Mr. Stern has over 25 years of venture capital and investment banking experience focusing primarily on the life science and technology sectors of the capital markets. Mr. Stern has completed over 100 transactions throughout his career, including private placements, public offerings and mergers and acquisitions, valued in excess of several billion dollars.
Mr. Stern currently serves as a Director of Dance Bipharm, Inc., and Matinas BioPharma Holdings, Inc. (OTCBB: MTNB). He is a former Director of InVivo Therapeutics Holdings Corp. (OTCQB: NVIV), Organovo Holdings, Inc. (NYSE MKTS: ONVO), Prolor Biotech (formerly NYSE MKTS: PBTH), and Labstyle Innovations Corporation (OTCQB: DRIO). In 2013, Prolor was acquired by OPKO Health, Inc. (NYSE: OPK) for over $500 million.
Mr. Stern has been a keynote speaker and conference panelist nationally on topics ranging from Venture Capital to Alternative Public Offerings.
Prior to being Head of Private Equity Banking at Aegis Capital and CEO of SternAegis Ventures, Mr. Stern was the Senior Managing Director at Spencer Trask Ventures from 1997 to 2012 and was at Josephthal & Co., from 1989 to 1997 as Senior Vice President and Managing Director of Private Equity Marketing. Mr. Stern has been a FINRA licensed securities broker since 1987 and a General Securities Principal since 1991.